

## 1. INTRODUCTIONS

- a. Jeremy ‘re-welcomed’ Euphrasia Ebai-Atuh Ndi, a citizen partner from Cameroon
- b. He also welcomed Justine Karpusheff, a representative from NICE

## 2. REVIEW OF COVID-END ACTION ITEMS

- a. Jeremy pointed partners to the notes from 3 June (see attachment 2)

## 3. COVID-END NETWORK UPDATES

- a. Jeremy introduced potential COVID-END legacy projects and asked partners to consider the legacies they would like to leave as partners in COVID-END and as members of particular COVID-END working groups
  - i. WG1 Scoping - Lancet paper authored by COVID-END partners
  - ii. WG2 Prioritizing - Excel, matchmaking & paper
  - iii. WG3 Accessing - inventory/database +/- transition to lessons learned for future
  - iv. WG4 Engaging - GCESC exhibits via webinars and listserv
  - v. WG5 Recommending - retired(?) (the legacy was resources)
  - vi. WG6 Sustaining - evaluation paper(s)
  - vii. WG7 Advocating - Cochrane convenes event
  - viii. TG1 Equity - addition of column to inventory
  - ix. TG2 Citizen partners – paper

Kerry noted that it would be good to also produce a cross-cutting paper on the COVID-END experiment across all working groups and other activities (and Jeremy and David Gough suggested that this may be something that the Scoping working group could take up)

**ACTION: Working-group co-chairs to consider initiating discussions about legacy projects with their respective working groups**

- b. John provided an update on the Global Commission on Evidence to Address Societal Challenges
  - i. Eight commissioners have been confirmed and we are awaiting confirmations from additional commissioners
  - ii. Some funding has been confirmed and many promising conversations with potential funders are underway
  - iii. Report will comprise six chapters, be ‘exhibits’ heavy (with many infographics, etc.), include recommendations (and note where recommendations align with those from other commissions), and be published in six languages; feedback on draft exhibits will be elicited over the coming months
  - iv. Timeline includes a six-month-long report-preparation process (June to November, with the report being published in December) and with 2022 being about pursuing pathways to influence

- v. Pathways to influence include advisors (intermediary organizations and individuals with a deep familiarity with the four types of decision-makers, related commissions and initiatives, and funders), events (where feedback on the exhibits can be elicited and pathways to influence pursued), COVID-END partners (who we hope will provide input and promote recommendations), and electronic mechanisms (e.g., listservs, webinars, etc.)
- vi. There are two current requests of COVID-END partners, which are listed below as actions
- c. **ACTION: Partners to review the draft exhibit listing key developments in the field of using evidence to address societal challenges and suggest any that are missing**
- d. **ACTION: Partners to review the list of key meetings being planned over the next year and suggest any that are missing**
- e. Partners agreed to change the COVID-END partners meeting frequency to monthly  
**ACTION: Safa to update the calendar invitations to include only the following dates:**
  - i. July 29
  - ii. September 9
  - iii. Early to mid October (exact date to be confirmed)
  - iv. November 4
  - v. December 2

#### 4. NEWS AND INITIATIVES OF INTEREST TO PARTNERS

- a. Zac Munn introduced the Guidelines International Network (GIN)'s 2021 annual conference – “Future forward: Relevant, implementable and sustainable guidelines”
  - i. Dates: 25 to 27 October 2021
  - ii. Abstract submission and registration now open
  - iii. For more information, link [here](#)
- b. Zac also described a cross-partner event bringing together evidence and guideline groups from Australia and New Zealand: <https://www.engagingevidence.com> (November 2021)

#### 5. ANY OTHER BUSINESS

- a. Jeremy suggested that we bring back to a future meeting a point raised by Maureen Dobbins in the chat box: “For consideration, not necessarily for discussion today, do you see COVID-END continuing in some way post COVID to continue: collaborating on producing high quality evidence syntheses in response to decision/policy maker needs, reduce duplication, continue to discuss and debate methods for rapid reviews and other knowledge products; and continue to evolve methods for measuring/gauging impact?”
- b. **ACTION: Safa to add this to a future agenda**
- c. Kerry Albright noted that UNICEF Innocenti has “several individual evidence synthesis consultancies coming up at UNICEF-Innocenti to help produce EGM's/Rapid Evidence Assessments on Children and Adolescents and (i) mental health (ii) child labour and education and (iii) disability”
- d. **ACTION: Kerry to share vacancy announcements via Twitter, tagging COVID-END, and partners to consider sharing among their networks**

